Статины в первичной профилактике сердечно-сосудистых заболеваний
- Авторы: Кобалава Ж.Д.1, Виллевальде С.В.1, Kobalava GD2, Villevalde SV2
-
Учреждения:
- Российский университет дружбы народов, Москва
- Russian University of Peoples' Friendship, Moscow
- Выпуск: Том 83, № 9 (2011)
- Страницы: 70-75
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/30940
- ID: 30940
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
Жанна Давидовна Кобалава
Российский университет дружбы народов, Москвад-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней РУДН; Российский университет дружбы народов, Москва
Светлана Вадимовна Виллевальде
Российский университет дружбы народов, Москва
Email: villevaldes@mail.ru
д-р мед. наук, проф., каф. пропедевтики внутренних болезней РУДН; Российский университет дружбы народов, Москва
G D Kobalava
Russian University of Peoples' Friendship, MoscowRussian University of Peoples' Friendship, Moscow
S V Villevalde
Russian University of Peoples' Friendship, MoscowRussian University of Peoples' Friendship, Moscow
Список литературы
- Национальные рекомендации по кардиоваскулярной профилактике в клинической практике (проект.). http://scardio.ru/recommendations/draft001CD/default.asp
- Оганов Р. Г. (ред.) Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: Нац. клинические рекомендации. Сборник. 3-е изд. М.: Изд-во "Силицея-Полиграф"; 2010. 192-274.
- Grundy S. M., Cleeman J. I., Merz C. N. et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications or recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; l10: 227-239.
- European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prevent. Rehabil. 2007; 4 (Suppl. 2).
- Ridker P. M., Danielson E., Fonseca F. et al for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-2207.
- Hlatky M. A. Expanding the orbit of primary prevention - moving beyond JUPITER. N. Engl. J. Med. 2008; 359: 2280- 2282.
- Ridker P. M., Danielson E., Fonseca F. A. H. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
- Glynn R. J., Danielson E., Fonseca F. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
- Everett B. M., Glynn R. J., MacFadyen J. G., Ridker P. M. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein. Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121: 143-150.
- Goldstein L. B., Bushnell C. D., Adams R. J. et al. Guidelines for the primary prevention of stroke. A Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, published online Dec 6, 2010; http://stroke.ahajournals.org, doi:10.1161/ STR.0b013e3181fcb238.
- Glynn R. J., Koenig W., Nordestgaard B. G. et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann. Intern. Med. 2010; 152(8): 488-496.
- Mora S., Glynn R. J., Hsia J. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-1077.
- Ridker P. M., MacFadyen J., Cressman M., Glynn R. J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein. A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 2010; 55: 1266-1273.
- Ridker P. M., MacFadyen J. G., Nordestgaard B. G. et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk". Circ. Cardiovasc. Qual. Outcomes 2010; 3: 447-452.
- Ridker P. M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001; 344: 1959-1965.
- Yang E. Y., Nambi V., Tang Z. et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a US Population: insights from the ARIC (Atherosclerosis Risk in Communities) Study. J. Am. Coll. Cardiol. 2009; 54: 2388-2395.
- McMurray J. J. V., Kjekshus J., Gullestad L. et al. for the CORONA Study Group. Effects of statin therapy according to plasma highsensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-2196.
- ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2010; 56(25): 2l82-2199.
- Genest J., McPherson R., Frohlich J. et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention or cardiovascular disease in the adult - 2009 recommendations. Can. J. Cardiol. 2009; 25(10): 567-579.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200128.htm
- http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm199891.htm
- Ridker P. M., Glynn R. J. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010; 375: 2071.
- Brugts J. J., Yetgin T., Hoeks S. E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br. Med. J. 2009; 338: b2376.
- Ray K. K., Seshasai S. R. K., Erqou S. et al. Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch. Intern. Med. 2010; 170: 1024-1031.